Premium
Dysplastic urothelial changes accompany empagliflozin administration in urinary bladder of experimental diabetes
Author(s) -
AbdelHamid Ahmed A. M.,
Firgany Alaa ElDin L.
Publication year - 2019
Publication title -
international journal of experimental pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.671
H-Index - 72
eISSN - 1365-2613
pISSN - 0959-9673
DOI - 10.1111/iep.12343
Subject(s) - urothelium , empagliflozin , empa , medicine , diabetes mellitus , urology , diabetic nephropathy , urinary system , urinary bladder , endocrinology , type 2 diabetes , chemistry , mineralogy , electron microprobe
Summary Empagliflozin (EMPA) is a promising novel antidiabetic drug; however, doubts have been raised regarding its use and the increased risk of urinary bladder carcinoma. In this study, we evaluated urothelium expression of cytokeratins (CKs) and Ki‐67 proliferative activity in the urinary bladder of diabetic (DM + EMPA) and non‐diabetic rats after EMPA administration. By routine histology, dysplastic changes were detected in the urothelium of diabetic as well as non‐diabetic animals after EMPA administration. Moreover, the expression of CK‐7 and CK‐8 was significantly decreased ( P < .05) while that of CK‐20 as well as Ki‐67 was significantly increased ( P < .05) in EMPA per se and DM + EMPA urothelium groups compared to that of control and diabetics. The dysplastic changes together with the increased proliferative activity in urothelium after EMPA administration provide a cellular evidence that supports the former clinical concerns.